{"created":"2024-10-23T01:27:02.629466+00:00","id":2000968,"links":{},"metadata":{"_buckets":{"deposit":"c9f74b94-0d7c-4999-ac77-719abdc239c6"},"_deposit":{"created_by":15,"id":"2000968","owner":"15","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"2000968"},"status":"published"},"_oai":{"id":"oai:mie-u.repo.nii.ac.jp:02000968","sets":["631:636:1728958087061"]},"author_link":[],"item_8_biblio_info_6":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-05-17","bibliographicIssueDateType":"Issued"}}]},"item_8_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"文献またはインタビューフォームから、各薬物の薬物動態の情報を収集し、エルロチニブ、レテルモビル、ミロガバリン、オラパリブ、バリシチニブ、アビラテロン、6－メルカプトプリンの7剤について、生理学的薬物動態（PBPK）プロトタイプを作成してDDI Simulator V.2.6（富士通株式会社）に登録した。一例として、オラパリブ300mgＸ2/日について、強力なCYP3A4阻害薬であるイトラコナゾール（100mgＸ1/日）、クラリスロマイシン（200mgＸ2/日）との定常状態における相互作用についてシミュレーションを行い、オラパリブのＡＵＣはそれぞれ1.50倍、2.05倍の上昇と予測された。","subitem_description_language":"ja","subitem_description_type":"Abstract"},{"subitem_description":"Information on the pharmacokinetics of each drug was collected from the literature or interview forms, and Physiological based pharmacokinetic (PBPK) prototypes were created for seven drugs: Erlotinib, Letermovir, Mirogabalin, Olaparib, Baricitinib, Abiraterone, 6-Mercaptopurine, and registered in DDI Simulator V.2.6 (Fujitsu Limited). As an example, the\nsteady-state interactions of Olaparib 300 mgX2/day with the potent CYP3A4 inhibitors Itraconazole (100 mgX1/day) and Clarithromycin (200 mgX2/day) were simulated, and the AUC of olaparib was 1.50-and 2.05-fold increase was predicted.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_8_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"2020年度～2022年度科学研究費補助金(基盤研究(C))研究成果報告書","subitem_description_type":"Other"}]},"item_8_description_64":{"attribute_name":"科研費番号","attribute_value_mlt":[{"subitem_description":"20K07130","subitem_description_type":"Other"}]},"item_8_publisher_30":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"三重大学"}]},"item_8_text_31":{"attribute_name":"出版者（ヨミ）","attribute_value_mlt":[{"subitem_text_value":"ミエダイガク"}]},"item_8_text_65":{"attribute_name":"item_8_text_65","attribute_value_mlt":[{"subitem_text_value":"Kaken / 科研費報告書"}]},"item_8_version_type_15":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岩本, 卓也","creatorNameLang":"ja"},{"creatorName":"IWAMOTO, TAKUYA","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"中谷, 中","creatorNameLang":"ja"},{"creatorName":"Nakatani, Kaname","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"齋藤, 佳菜子","creatorNameLang":"ja"},{"creatorName":"Saito, Kanako","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2024-10-23"}],"filename":"2024RP0058.pdf","filesize":[{"value":"624 KB"}],"format":"application/pdf","url":{"label":"2024RP0058.pdf","url":"https://mie-u.repo.nii.ac.jp/record/2000968/files/2024RP0058.pdf"},"version_id":"77b9486f-9d50-4612-94ae-30449072d627"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"PBPKモデル解析","subitem_subject_scheme":"Other"},{"subitem_subject":"オラパリブ","subitem_subject_scheme":"Other"},{"subitem_subject":"相互作用","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"がんゲノム薬理情報とTDMを活用した個別化薬物治療の実用化に向けた研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"がんゲノム薬理情報とTDMを活用した個別化薬物治療の実用化に向けた研究","subitem_title_language":"ja"},{"subitem_title":"Research on practical use of personalized targeting therapy in cancer using pharmacogenomic information and TDM","subitem_title_language":"en"}]},"item_type_id":"8","owner":"15","path":["1728958087061"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2024-10-23"},"publish_date":"2024-10-23","publish_status":"0","recid":"2000968","relation_version_is_last":true,"title":["がんゲノム薬理情報とTDMを活用した個別化薬物治療の実用化に向けた研究"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2024-10-23T01:36:55.717766+00:00"}